» Articles » PMID: 7858872

Evidence for P2-purinoceptor-mediated Inhibition of Noradrenaline Release in Rat Brain Cortex

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1994 Nov 1
PMID 7858872
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

1. Some postganglionic sympathetic axons possess P2Y-like P2-purinoceptors which, when activated, decrease the release of noradrenaline. We examined the question of whether such receptors also occur at the noradrenergic axons in the rat brain cortex. Slices of the brain cortex were preincubated with [3H]-noradrenaline, then superfused with medium containing desipramine (1 microM) and stimulated electrically, in most experiments by trains of 4 pulses/100 Hz. 2. The selective adenosine A1-receptor agonist, N6-cyclopentyl-adenosine (CPA; 0.03-3 microM) as well as the non-subtype-selective agonist 5'-N-ethylcarboxamido-adenosine (NECA; 0.3-3 microM) reduced the evoked overflow of tritium, whereas the adenosine A2a-receptor agonist, 2-p-(2-carbonylethyl)-phenethylamino-5'-N-ethylcarboxamido-a denosine (CGS-21680; 0.003-30 microM) and the adenosine A3-receptor agonist N6-2-(4-aminophenyl)ethyl-adenosine (APNEA; 0.03-3 microM) caused no change. Of the nucleotides tested, ATP (30-300 microM), adenosine-5'-O-(3-thiotriphosphate) (ATP gamma S; 30-300 microM), adenosine-5'-O-(2-thiodiphosphate) (ADP beta S; 30-300 microM), P1,P4-di(adenosine-5')-tetraphosphate (Ap4A; 30-300 microM) and the preferential P2Y-purinoceptor agonist, 2-methylthio-ATP (300 microM) decreased the evoked overflow of tritium. The P2X-purinoceptor agonist, alpha,beta-methylene-ATP (3-300 microM) caused no change. 3. The A1-selective antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 10 nM) attenuated the effects of the nucleosides CPA (apparent pKB value 9.8) and NECA as well as of the nucleotides ATP (apparent pKB 9.3), ATP gamma S (apparent pKB 9.2) and ADP beta S (apparent pKB 8.7). CGS-21680 and APNEA were ineffective also in the presence of DPCPX. The A2-selective antagonist 1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KF-17837) reduced the effects of CPA, NECA and ATP gamma S only when given at a concentration of 300 nM but not at 1O nM.4. The P2-purinoceptor antagonists, suramin (300 micro M), reactive blue 2 (30 micro M) and cibacron blue 3GA(30 micro M) did not change the effect of CPA. Suramin and cibacron blue 3GA shifted the concentration response curve of ATP gamma S to the right (apparent pKB values 3.7 and 5.0, respectively). Reactive blue 2 also attenuated the effect of ATPyS, and cibacron blue 3GA attenuated the effect of ATP, but in these cases the agonist concentration-response curves were not shifted to the right. There was no antagonistic effect of suramin against ATP and ADP beta S.5. The results indicate that rat cerebrocortical noradrenergic axons possess, in addition to the knownadenosine Al-receptor, a separate purinoceptor for nucleotides (P2) which, in contrast to the Al-receptor,is blocked by suramin, reactive blue 2 and cibacron blue 3GA. Nucleotides such as ATP and ATP gamma S activate both receptors. Inconsistencies in antagonist effects against nucleotides are probably due to this activation of two receptors. The presynaptic P2-purinoceptor is P2Y-like, as it is in the peripheral sympathetic nervous system.

Citing Articles

Involvement of P2Y, P2Y, A and A Receptors in the Purinergic Inhibition of NMDA-Evoked Noradrenaline Release in the Rat Brain Cortex.

Quintas C, Goncalves J, Queiroz G Cells. 2023; 12(13).

PMID: 37443726 PMC: 10341078. DOI: 10.3390/cells12131690.


Activation of basal forebrain purinergic P2 receptors promotes wakefulness in mice.

Yang C, Larin A, McKenna J, Jacobson K, Winston S, Strecker R Sci Rep. 2018; 8(1):10730.

PMID: 30013200 PMC: 6048041. DOI: 10.1038/s41598-018-29103-4.


Neurochemical and electrical modulation of the locus coeruleus: contribution to CO2drive to breathe.

de Carvalho D, Patrone L, Taxini C, Biancardi V, Vicente M, Gargaglioni L Front Physiol. 2014; 5:288.

PMID: 25183958 PMC: 4135231. DOI: 10.3389/fphys.2014.00288.


P2Y receptors in Alzheimer's disease.

Erb L, Cao C, Ajit D, Weisman G Biol Cell. 2014; 107(1):1-21.

PMID: 25179475 PMC: 4286471. DOI: 10.1111/boc.201400043.


P2 receptor-mediated modulation of neurotransmitter release-an update.

Sperlagh B, Heinrich A, Csolle C Purinergic Signal. 2008; 3(4):269-84.

PMID: 18404441 PMC: 2072919. DOI: 10.1007/s11302-007-9080-0.


References
1.
von Kugelgen I, Kurz K, Starke K . Axon terminal P2-purinoceptors in feedback control of sympathetic transmitter release. Neuroscience. 1993; 56(2):263-7. DOI: 10.1016/0306-4522(93)90330-i. View

2.
Barnard E, Burnstock G, Webb T . G protein-coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol Sci. 1994; 15(3):67-70. DOI: 10.1016/0165-6147(94)90280-1. View

3.
Miyahara H, Suzuki H . Pre- and post-junctional effects of adenosine triphosphate on noradrenergic transmission in the rabbit ear artery. J Physiol. 1987; 389:423-40. PMC: 1192088. DOI: 10.1113/jphysiol.1987.sp016664. View

4.
Lohse M, Klotz K, Reddington M, Schwabe U, Olsson R . 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(2):204-10. DOI: 10.1007/BF00165806. View

5.
Dunn P, BLAKELEY A . Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol. 1988; 93(2):243-5. PMC: 1853806. DOI: 10.1111/j.1476-5381.1988.tb11427.x. View